NCT02915705 - Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2016

Primary Completion Date

February 12, 2018

Study Completion Date

July 15, 2019

Conditions

X-Linked Hypophosphatemia

Interventions

BIOLOGICAL

burosumab

solution for subcutaneous (SC) injection

DRUG

Oral Phosphate Supplement

oral tablet; oral solution; oral powder

DRUG

active vitamin D

tablet, oral solution

Trial Locations (16)

2145

The Children's Hospital at Westmead, Westmead

17176

Karolinska Institutet and University Hospital, Stockholm

37232

Vanderbilt Children's Hospital, Nashville

46202

Indiana University School of Medicine, Indianapolis

63110

Shriners Hospital For Children, St Louis

90027

Children's Hospital Los Angeles, Los Angeles

94158

UCSF, San Francisco

K1H 8L1

Children's Hospital of Eastern Ontario (CHEO) Research Institute, Ottawa

M5G 1X8

The Hospital for Sick Children, Toronto

H4A 0A9

Shriners Hospital for Children - Canada, Montreal

232-8555

Kanagawa Children's Medical Center, Yokohama

700-0013

Okayama Saiseikai General Hospital, Okayama

553-0003

Japan Community Healthcare Organization Osaka Hospital, Osaka

03080

Seoul National University Hospital, Seoul

B4 6NH

Birmingham Children's Hospital, Birmingham

M13 9WL

Royal Manchester Children's Hospital - University of Manchester, Manchester